Novo Nordisk A/s

Kristian Sass-Oerum

Henning Thoegersen

Birgit Wieczorek

Sebastian Beck Joergensen

Tina Moeller Tagmose

Birgitte Andersen

Joergen Olsen

Yi Wang

Xiang Gao

Hongtao Guan

Sven Hastrup

Kristian Tage Hansen

Lars Fogh Iversen

Xujia Zhang

Allan Christian Shaw

Per Noergaard

Kim Vilbour Andersen

Charlotte Helgstrand

Kilian Waldemar Conde Frieboes

Michael Paolo Bastner Sandrini

Michael P Bastner Sandrini

The invention relates to MIC-1 compounds. More specifically it relates to compounds comprising a MIC-1 polypeptide and an N-terminal amino acid extension, wherein said extension consists of 3 to 36 amino acid residues and where the compound has a calculated pI lower than 6.5. The compounds of the invention have MIC-1 activity. The invention also relates to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable excipients, as well as the medical use of the compounds.

MIC-1 compounds and use thereof

The invention relates to MIC-1 compounds. More specifically it relates to compounds comprising a MIC-1 polypeptide with an N-terminal amino acid extension and a protractor wherein the amino acid extension comprises 3 to 36 amino acid residues and where the MIC-1 polypeptide and the N-terminal amino acid extension together have a calculated pI lower than 6.5. The compounds of the invention have MIC-1 activity. The invention also relates to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable excipients, as well as the medical use of the compounds.

MIC-1 compounds and uses thereof

The invention relates to a derivative of a FGF21 protein having a cysteine residue at a position corresponding to position 167, 169, 170, 171, 172, 173, 174, 175 and in particular position 180 or position 181 of mature human FGF21 and derivatives thereof having a side chain attached to this cysteine. The FGF21 derivatives of the invention display high potency towards the FGF receptors. The invention also relates to pharmaceutical compositions comprising such FGF21 derivatives and pharmaceutically acceptable excipients, as well as the medical use of the FGF21 derivatives.

FGF21 derivatives and uses thereof

The invention relates to MIC-1 fusion proteins. More specifically it relates to compounds comprising fusion proteins comprising a MIC-1 protein or an analog thereof at the C-terminus of the fusion protein and a functional variant of human serum albumin at the N-terminus of the fusion protein connected via a peptide linker. The compounds of the invention have MIC-1 activity. The invention also relates to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable excipients, as well as the medical use of the compounds.

MIC-1 fusion proteins and uses thereof

Growing community of inventors

Koebenhavn, Denmark

Kristian Sass-Oerum